TMEM230 Gene

TMEM230 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">tmem230</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>TMEM230</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Transmembrane Protein 230</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>20p13</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>138802</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000167840</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9H0Y7</td>
</tr>
<tr>
<td class="label">Gene Family</td>
<td>TMEM230/C20orf30 family</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Parkinson's Disease, Dementia with Lewy Bodies, Corticobasal Degeneration</td>
</tr>
<tr>
<td class="label">Inheritance Pattern</td>
<td>Autosomal Dominant</td>
</tr>
<tr>
<td class="label">Age of Onset</td>
<td>45-55 years (familial cases)</td>
</tr>
<tr>
<td class="label">Compartment</td>
<td>Function</td>
</tr>
<tr>
<td class="label">Synaptic Vesicles</td>
<td>Regulates vesicle cycling</td>
</tr>
<tr>
<td class="label">Early Endosomes</td>
<td>Controls endosomal sorting</td>
</tr>
<tr>
<td class="label">Recycling Endosomes</td>
<td>Facilitates cargo return</td>
</tr>
<tr>
<td class="label">Mitochondria</td>
<td>Energy metabolism</td>
</tr>
<tr>
<td class="label">Autophagosomes</td>

TMEM230 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">tmem230</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>TMEM230</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Transmembrane Protein 230</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>20p13</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>138802</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000167840</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9H0Y7</td>
</tr>
<tr>
<td class="label">Gene Family</td>
<td>TMEM230/C20orf30 family</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Parkinson's Disease, Dementia with Lewy Bodies, Corticobasal Degeneration</td>
</tr>
<tr>
<td class="label">Inheritance Pattern</td>
<td>Autosomal Dominant</td>
</tr>
<tr>
<td class="label">Age of Onset</td>
<td>45-55 years (familial cases)</td>
</tr>
<tr>
<td class="label">Compartment</td>
<td>Function</td>
</tr>
<tr>
<td class="label">Synaptic Vesicles</td>
<td>Regulates vesicle cycling</td>
</tr>
<tr>
<td class="label">Early Endosomes</td>
<td>Controls endosomal sorting</td>
</tr>
<tr>
<td class="label">Recycling Endosomes</td>
<td>Facilitates cargo return</td>
</tr>
<tr>
<td class="label">Mitochondria</td>
<td>Energy metabolism</td>
</tr>
<tr>
<td class="label">Autophagosomes</td>
<td>Autophagy regulation</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Substantia Nigra</td>
<td>High</td>
</tr>
<tr>
<td class="label">Ventral Tegmental Area</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Striatum</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebral Cortex</td>
<td>Moderate-High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Brainstem Nuclei</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>AAV-TMEM230</td>
</tr>
<tr>
<td class="label">Small Molecules</td>
<td>Trafficking modulators</td>
</tr>
<tr>
<td class="label">Protein Replacement</td>
<td>Recombinant TMEM230</td>
</tr>
<tr>
<td class="label">Gene Editing</td>
<td>CRISPR correction</td>
</tr>
<tr>
<td class="label">Partner Protein</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">Synaptophysin</td>
<td>Physical binding</td>
</tr>
<tr>
<td class="label">SV2</td>
<td>Physical binding</td>
</tr>
<tr>
<td class="label">SNAP-25</td>
<td>Functional interaction</td>
</tr>
<tr>
<td class="label">Synaptotagmin</td>
<td>Ca2+ sensing</td>
</tr>
<tr>
<td class="label">Clathrin</td>
<td>Endocytosis</td>
</tr>
<tr>
<td class="label">Rab GTPases</td>
<td>Trafficking control</td>
</tr>
</table>

Introduction

TMEM230 (Transmembrane Protein 230) is a nuclear-encoded mitochondrial protein that has emerged as a significant genetic risk factor in neurodegenerative diseases, particularly [Parkinson's disease (PD)](/diseases/parkinsons-disease), [dementia with Lewy bodies (DLB)](/diseases/lewy-body-dementia), and [corticobasal degeneration (CBD)](/diseases/corticobasal-syndrome). Initially identified through genetic studies of familial PD cases, TMEM230 encodes a transmembrane protein localized primarily to synaptic vesicles, endosomes, and mitochondria [@tmem230_pd].

The discovery of pathogenic TMEM230 mutations provided crucial insights into the molecular mechanisms underlying neurodegeneration, particularly the role of synaptic vesicle trafficking and endosomal-lysosomal dysfunction in the pathogenesis of synucleinopathies. This gene represents an important therapeutic target for development of disease-modifying treatments for PD and related disorders.

Gene Overview

Molecular Biology

Gene Structure

The TMEM230 gene spans approximately 15.5 kb on chromosome 20p13 and consists of 7 coding exons that encode a protein of 175 amino acids. The gene structure is relatively simple, with the majority of pathogenic mutations concentrated in the coding region [@tmem230_family].

Protein Structure

TMEM230 is a small multi-pass transmembrane protein with several key structural features:

• Transmembrane Domains: The protein contains 3-4 predicted transmembrane helices that anchor it to membrane compartments
• N-terminal Domain: Cytoplasmic N-terminus involved in protein-protein interactions
• C-terminal Tail: Cytoplasmic C-terminus containing potential phosphorylation sites
• Mitochondrial Targeting Sequence: N-terminal targeting sequence directing import to mitochondria

Subcellular Localization

TMEM230 exhibits a complex subcellular distribution that explains its involvement in multiple cellular processes:

The localization to synaptic vesicles is particularly relevant to dopaminergic neurons in the [substantia nigra pars compacta](/brain-regions/substantia-nigra), which are selectively vulnerable in PD.

Cellular Functions

Synaptic Vesicle Trafficking

TMEM230 plays a critical role in synaptic vesicle cycling, a process essential for neurotransmitter release [@tmem230_sv]:

The protein interacts with components of the synaptic vesicle trafficking machinery, including synaptophysin, SV2, and SNARE proteins. Loss of TMEM230 function impairs dopamine release from presynaptic terminals, leading to synaptic dysfunction.

Endosomal Sorting

TMEM230 is involved in endosomal sorting pathways that regulate membrane protein trafficking [@endosomal_pd]:

• Cargo Recognition: Recognizes sorting motifs in transmembrane proteins
• Endosomal Maturation: Regulates transition from early to late endosomes
• Recycling: Facilitates return of cargo to the plasma membrane via recycling endosomes
• Lysosomal Delivery: Directs proteins to lysosomal degradation pathways

Autophagy Regulation

TMEM230 participates in autophagy-lysosome pathways critical for protein quality control [@tmem230_autophagy]:

• Autophagosome Formation: Required for nucleation of autophagic vesicles
• Cargo Recognition: Facilitates recognition of protein aggregates
• Lysosomal Fusion: Regulates autophagosome-lysosome fusion
• Mitochondrial Quality Control: Participates in mitophagy

Disease Associations

Parkinson's Disease

TMEM230 was identified as a causative gene for familial PD through genetic studies of multi-generational families with autosomal dominant inheritance [@tmem230_pd]:

Genetics:

• Missense mutations (p.Arg141His, p.Tyr87Asn, p.Pro85Leu) cause loss-of-function
• Mutations exhibit autosomal dominant inheritance with high penetrance
• Geographic clustering suggests founder effects in certain populations

• Typical PD phenotype: resting tremor, bradykinesia, rigidity, levodopa response
• Age of onset: 45-55 years (earlier than sporadic PD)
• Disease duration: 10-15 years to endpoint
• Motor fluctuations and dyskinesias develop with disease progression

• Lewy bodies (alpha-synuclein positive) in substantia nigra and cortex
• Neuronal loss in substantia nigra pars compacta
• Variable involvement of brainstem and cortical regions
• Dopaminergic neuron degeneration in ventral midbrain

Dementia with Lewy Bodies

TMEM230 variants contribute to DLB pathogenesis through overlapping mechanisms [@tmem230_dlb]:

• The protein localizes to Lewy bodies, indicating direct involvement in aggregation
• Synaptic dysfunction contributes to cortical impairment
• Endosomal alterations affect protein clearance
• Neuroinflammation accompanies pathology

• Fluctuating cognition with pronounced variations
• Visual hallucinations
• Parkinsonism
• REM sleep behavior disorder
• Autonomic dysfunction

Corticobasal Degeneration

TMEM230 mutations have been reported in CBD cases, expanding the phenotypic spectrum [@tmem230_cbd]:

• CBD is a 4R-tauopathy with asymmetric parkinsonism
• TMEM230 mutations may interact with tau pathology
• Overlapping features with [progressive supranuclear palsy (PSP)](/diseases/progressive-supranuclear-palsy)
• Cortical sensory loss and apraxia are characteristic

Expression Pattern

TMEM230 exhibits neuron-specific expression with high levels in brain regions affected in movement disorders:

Expression data from the [Allen Human Brain Atlas](https://human.brain-map.org/microarray/search/show?search_term=TMEM230) confirms neuron-enriched expression patterns.

Animal Models

Mouse Models

Several mouse models have been developed to study TMEM230 function:

Knockout Models:

• Constitutive knockout: Neonatal lethality, indicating essential developmental function
• Conditional knockout in dopaminergic neurons: Progressive motor deficits
• Conditional knockout in forebrain: Learning and memory impairments

• Wild-type TMEM230 overexpression: Rescues synaptic deficits in knockout mice
• Mutant TMEM230 expression: Recapitulates PD-like features
• Humanized models: Express human TMEM230 with patient mutations

Zebrafish Models

Zebrafish provide valuable insights into developmental functions:

• Morpholino knockdown: Motor deficits and embryonic lethality
• CRISPR knockouts: Developmental defects in dopaminergic neuron development
• Toxicity models: Alpha-synuclein-induced phenotypes exacerbated by TMEM230 loss

Key Findings from Animal Studies

Therapeutic Approaches

Gene Therapy

AAV-based gene therapy represents a promising approach:

• Vector: AAV2/9 for neuronal tropism
• Promoter: Synapsin or CamKII for neuron-specific expression
• Approach: Deliver wild-type TMEM230 to restore function
• Status: Preclinical development
• Challenges: Proper dosing, immune response, long-term expression

Small Molecule Modulators

Drug discovery efforts target TMEM230 function:

• Trafficking Modulators: Enhance TMEM230 trafficking to synaptic vesicles
• Stabilizers: Stabilize TMEM230 protein structure
• Function Enhancers: Increase synaptic vesicle cycling efficiency
• Screening Approaches: High-throughput screening for small molecules

Protein Replacement

Alternative approaches include protein delivery:

• Recombinant Protein: Deliver functional TMEM230
• Engineering: Develop cell-penetrating forms
• Status: Early research stage

Gene Editing

CRISPR-based approaches offer precise correction:

• Base Editing: Correct specific point mutations
• CRISPR-Cas9: Disrupt pathogenic mutations
• Prime Editing: Insert wild-type sequence
• Delivery: AAV or lipid nanoparticles

Biomarker Potential

TMEM230 as a biomarker offers several advantages:

Genetic Biomarkers

• Diagnostic: TMEM230 mutation testing for familial cases
• Prognostic: Earlier onset in mutation carriers
• Predictive: Response to specific therapies

Fluid Biomarkers

• CSF TMEM230: Potential for disease monitoring
• Blood TMEM230: Less invasive sampling
• Correlation: Levels with disease severity

Imaging Biomarkers

• DaTscan: Dopaminergic neuron loss
• MRI: Structural changes in affected regions
• PET: Functional assessments

Research Directions

Several critical questions remain unanswered:

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dementia with Lewy Bodies](/diseases/lewy-body-dementia)
• [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Synaptic Vesicle Trafficking Pathway](/mechanisms/synaptic-vesicle-recycling)
• [Endosomal-Lysosomal Pathway](/mechanisms/endosomal-trafficking)
• [Autophagy-Lysosome Pathway](/mechanisms/autophagy-lysosome-neurodegeneration)
• [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)
• [Substantia Nigra](/brain-regions/substantia-nigra)

External Resources

• [NCBI Gene: TMEM230](https://www.ncbi.nlm.nih.gov/gene/138802)
• [UniProt: TMEM230](https://www.uniprot.org/uniprot/Q9H0Y7)
• [Ensembl: TMEM230](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167840)
• [GeneCards: TMEM230](https://www.genecards.org/cgi-bin/carddisp.pl?gene=TMEM230)
• [OMIM: TMEM230](https://www.omim.org/entry/614337)
• [Allen Human Brain Atlas](https://human.brain-map.org/microarray/search/show?search_term=TMEM230)
• [BrainSpan Atlas](https://www.brainspan.org/)

References

TMEM230 and Synaptic Vesicle Biology: Deep Dive

The Synaptic Vesicle Cycle

The synaptic vesicle cycle is a highly orchestrated process essential for neurotransmission [@synaptic_vesicle_cycling]. TMEM230 plays a critical role at multiple stages:

Stage 1: Vesicle Biogenesis

• Synaptic vesicles form at the presynaptic terminal
• TMEM230 participates in vesicle formation from endosomes
• Regulates sorting of vesicle components

• Neurotransmitters are packaged into vesicles
• TMEM230 affects dopamine packaging efficiency
• Regulates vesicle proton gradient

• Vesicles are positioned at active zones
• TMEM230 interacts with SNARE proteins
• Facilitates proper docking complex formation

• Ca2+ triggers fusion pore opening
• SNARE complex mediates membrane fusion
• TMEM230 regulates fusion kinetics

• Endocytosis retrieves vesicle components
• TMEM230 controls recycling endosome function
• Ensures proper reformation of synaptic vesicles

Molecular Interactions

TMEM230 interacts with several key proteins:

TMEM230 in Neurodegenerative Disease Mechanisms

Alpha-Synuclein Connection

The relationship between TMEM230 and alpha-synuclein is bidirectional [@synuclein_trafficking]:

Alpha-Synuclein Effects on TMEM230:

TMEM230 Effects on Alpha-Synuclein:

Tau Pathology Overlap

In corticobasal degeneration, TMEM230 intersects with tau pathology [@tmem230_cbd]:

• Cross-Seeding: Tau and alpha-synuclein can co-aggregate
• **Vulnerability: 4R-tauopathies show selective neuron loss
• Therapeutic Implications: Dual-target approaches may be needed

Mitochondrial Contributions

TMEM230 localizes to mitochondria in some cell types, contributing to [@pd_mitochondrial]:

• ATP Production: Affects mitochondrial function
• Calcium Handling: Regulates mitochondrial calcium
• ROS Generation: Contributes to oxidative stress
• Apoptosis: Influences cell death pathways

Clinical Considerations

Genetic Testing

Indications for Testing:

• Family history of PD with autosomal dominant inheritance
• Early-onset PD (<50 years)
• Presence of Lewy body pathology
• Dystonia or cognitive changes

• Multi-gene panel (includes TMEM230)
• Whole exome sequencing
• Confirmation with Sanger sequencing

• Pathogenic variants: Clear disease association
• Variants of uncertain significance: Require functional validation
• Benign variants: No clinical significance

Patient Management

Motor Symptoms:

• Levodopa/carbidopa: Primary treatment
• Dopamine agonists: Pramipexole, ropinirole
• MAO-B inhibitors: Selegiline, rasagiline
• Deep brain stimulation: For eligible patients

• Cognitive: Cholinesterase inhibitors
• Psychiatric: SSRIs, antipsychotics (carefully)
• Autonomic: Supportive management

• Gene therapy trials (AAV-TMEM230)
• Small molecule modulators (in development)
• Immunotherapy approaches (targeting alpha-synuclein)

Future Directions

Biomarker Development

Fluid Biomarkers:

• CSF alpha-synuclein seeds (PTM)
• Neurofilament light chain (NfL)
• TMEM230 levels (research)

• DaTscan: Dopaminergic terminal imaging
• PET: Tau and alpha-synuclein ligands
• MRI: Structural and functional measures

Therapeutic Pipeline

Near-term (1-3 years):

• Small molecule trafficking enhancers
• Antisense oligonucleotides
• Gene therapy vectors

• Optimized AAV delivery
• Combination therapies
• Biomarker-driven trials

• Gene editing approaches
• Cell replacement therapies
• Personalized medicine

Summary

TMEM230 represents a critical gene in the pathogenesis of neurodegenerative diseases, particularly Parkinson's disease, dementia with Lewy bodies, and corticobasal degeneration. Its role in synaptic vesicle trafficking, endosomal function, and autophagy places it at the intersection of multiple disease mechanisms. Understanding TMEM230 function provides insights into fundamental neuronal processes and identifies potential therapeutic targets. While current treatment options remain symptomatic, ongoing research into TMEM230-targeted therapies offers hope for disease-modifying interventions in the future.

Pathway Diagram

The following diagram shows the key molecular relationships involving tmem230 discovered through SciDEX knowledge graph analysis:

Pathway Diagram

The following diagram shows the key molecular relationships involving TMEM230 Gene discovered through SciDEX knowledge graph analysis: